High Dose Chemotherapy Followed By PBSC Rescue for HD

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186251
First received: September 13, 2005
Last updated: November 9, 2012
Last verified: July 2012

September 13, 2005
November 9, 2012
March 1998
Not Provided
  • Overall survival
  • FFS
  • Response rates
  • - Overall survival
  • - FFS
  • - Response rates
Complete list of historical versions of study NCT00186251 on ClinicalTrials.gov Archive Site
Toxicity of high dose chemotherapy
Same as current
Not Provided
Not Provided
 
High Dose Chemotherapy Followed By PBSC Rescue for HD
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hodgkin Disease
Procedure: high dose chemo then auto hematopoietic cell transplant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
July 2005
Not Provided

Inclusion Criteria:- adequate organ function

  • recurrent HD Exclusion Criteria:- CNS disease
  • no prior malignancy
Both
up to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00186251
BMT24, BMT24, 13322
Not Provided
Not Provided
Stanford University
Not Provided
Principal Investigator: Sally Arai Stanford University
Stanford University
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP